Stock Track | Grifols SA Soars 6.37% Intraday on Strong Q4 Financial Results

Stock Track

Feb 27, 2025

Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.

The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.

Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1176557824"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176557824\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176557824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176557824","market":"us","top_or_hot":-1,"title":"Stock Track | Grifols SA Soars 6.37% Intraday on Strong Q4 Financial Results","media":"Stock Track","content":"<p>Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.</p>\n\n<p>The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.</p>\n\n<p>Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Grifols SA Soars 6.37% Intraday on Strong Q4 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Grifols SA Soars 6.37% Intraday on Strong Q4 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 01:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.</p>\n\n<p>The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.</p>\n\n<p>Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRFS","symbol_name":"基立福","start_time":0,"source_url":"","article_id":"1176557824","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176557824","pubTimestamp":1740589848,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Grifols SA  shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching 1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRFS":"基立福"},"translate_title":"股票追踪Grifols SA因强劲的第四季度财务业绩盘中飙升6.37%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRFS":1},"content_text":"Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.\nThe company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.\nGrifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}